Evaluation of the Application of Intelligent Applications in Patients Undergoing Peritoneal Dialysis

NCT07612124 | Completed

• 1 other identifier: 2024167
• Study Type: interventional
• Target: 223
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to evaluate the value of a smart application named "Weiyin Health" in the follow-up management of patients undergoing peritoneal dialysis. The main questions it aims to answer are: Can the use of a smart application reduce the unplanned readmission rate? Can the use of a smart application reduce the incidence of peritonitis? Researchers will compare patients who use the smart application for follow-up with those who receive conventional follow-up. Eligible patients on peritoneal dialysis will be randomly assigned to one of two groups: one group will receive conventional follow-up (WeChat group + telephone reminders), and the other group will use the "Weiyin Health" smart application for follow-up (including data collection, AI-based Q\&A, follow-up reminders, and risk alerts). Both groups will attend peritoneal dialysis specialty clinic visits once every 3 months for routine check-ups over a 12-month period.

Conditions

Kidney Failure Chronic; ESRD (End-Stage Renal Disease)

Keywords

Smart application; Telemedicine; Peritoneal dialysis

Outcome Measures

Primary Outcomes (2)

• Unplanned Readmission Rate

  The proportion of participants who experience unplanned hospital readmission during the 12-month follow-up period.

  12 months

• Peritonitis Incidence

  The proportion of participants who develop peritonitis during the 12-month follow-up period. Peritonitis is defined according to the International Society for Peritoneal Dialysis (ISPD) criteria.

  12 months

Study Arms (2)

Conventional Follow-up Group

ACTIVE COMPARATOR

Participants in this group receive conventional follow-up care. Healthcare providers organize a WeChat group to regularly post peritoneal dialysis health knowledge and answer patients' questions. Traditional telephone calls are used for follow-up reminders. In addition, participants attend routine peritoneal dialysis specialty clinic follow-up visits once every 3 months for 12 months, including physical examination, PD catheter exit site examination, collection of blood/urine/peritoneal fluid samples, external tubing replacement every 6 months, and personalized health education.

Other: Conventional Follow-up

Smart Application Follow-up Group

EXPERIMENTAL

Participants in this group receive follow-up care via a smart application named "Weiyin Health". The application provides functions including data collection, AI-based one-on-one Q\&A, follow-up reminders, and risk alerts. In addition, participants attend routine peritoneal dialysis specialty clinic follow-up visits once every 3 months for 12 months, including physical examination, PD catheter exit site examination, collection of blood/urine/peritoneal fluid samples, external tubing replacement every 6 months, and personalized health education.

Device: Weiyin Health Smart Application

Interventions

Conventional Follow-up OTHER

Participants receive conventional follow-up care including a WeChat group for peritoneal dialysis health education and Q\&A, and telephone reminders for follow-up visits.

Conventional Follow-up Group

Weiyin Health Smart Application DEVICE

A smart application installed on participants' mobile devices that provides functions including data collection, AI-based one-on-one Q\&A, follow-up reminders, and risk alerts for peritoneal dialysis patients.

Also known as: Weiyin Health APP

Smart Application Follow-up Group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years 2.Willing and able to provide signed informed consent 3.Receiving maintenance peritoneal dialysis 4.Has basic reading and comprehension skills and is able to use Internet-based tools such as WeChat

You may not qualify if:

• \. History of peritonitis within the past 12 weeks, or active infection requiring systemic antibiotic therapy 2.Hospitalization within 4 weeks prior to screening 3.Severe heart failure (NYHA Class 4), severe malnutrition, malignancy, or any other condition that the investigator judges may affect the evaluation of outcomes 4.Currently participating in another clinical study 5.Psychiatric disorder or cognitive impairment

Sponsors & Collaborators

• The Third Xiangya Hospital of Central South University: lead

Study Sites (1)

Third Xiangya Hospital of Central South University

Changsha, Hunan, 410013, China

Location

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Masking Details: None (Open Label)
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief Pharmacist

Model Details: Participants are randomly assigned in a 1:1 ratio to one of two parallel groups: the conventional follow-up group or the smart application follow-up group.

Study Record Dates

• First Submitted: May 21, 2026
• First Posted: May 28, 2026
• Study Start: July 1, 2024
• Primary Completion: December 31, 2025
• Study Completion: April 1, 2026
• Last Updated: May 28, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)